Sleep Disruption During Adolescence: Effects on BMAL1 Gene Expression and Psychiatric Vulnerability

Sleep disruption (SD) is an increasingly alarming public health crisis with profound implications for psychiatric disorders. Particularly vulnerable are adolescents, who are in a critical period for brain development; insufficient sleep exacerbates neuro-developmental risks and predisposes to long-term cognitive and emotional deficits. A growing population with insomnia and other sleep disorders worldwide indicates the importance of understanding the underlying molecular mechanisms to develop targeted interventions. This study integrates clinical data, neurological studies, and molecular evidence from animal models to investigate the topic. Our analysis shows how the impacts of SD on circadian regulator BMAL1 impair prefrontal cortex (PFC) and hippocampus development, and how they are linked to common mood disorders such as depression and anxiety. Notably, key findings from the previous studies demonstrate that circadian misalignment in mice disrupts BMAL1 rhythms in prefrontal and hippocampal regions; in particular, it suppresses oligodendrocyte maturation genes and reduces myelination. Human clinical studies consistently link SD to mood disorders, while neurobiological evidence reveals the adolescent brain’s heightened vulnerability—a consequence of the ongoing maturation of the PFC, which governs emotional regulation and cognitive control. This developmental immaturity explains why teenagers are uniquely susceptible to sleep-related disruptions, often manifesting as heightened emotional reactivity and increased risk of mood disorders. Integrating these findings, this analysis identifies BMAL1-mediated oligodendrocyte dysfunction as a plausible pathway connecting sleep disruption to psychiatric risk. However, while animal models provide compelling evidence, the translational relevance to human adolescents requires further validation through longitudinal clinical studies and mechanistic investigations. Future research should prioritize direct targeting of SD-induced BMAL1 dysregulation and its downstream effects, with particular emphasis on developing personalized interventions tailored to individual circadian profiles and novel precision therapies optimized for adolescent neurodevelopmental windows.